Imagine being a child, full of dreams and energy, but trapped by a body that constantly fights against itself. That's the reality for many young Australians living with juvenile arthritis. But there's good news: the Australian government is expanding access to vital medicines through the Pharmaceutical Benefits Scheme (PBS), offering a lifeline to these kids and countless others battling debilitating conditions. This means more affordable treatments and a chance at a better quality of life. But here's where it gets controversial... How do we ensure these life-changing medications reach everyone who needs them, regardless of location or socioeconomic status?
The PBS has recently added several crucial medications to its list, providing subsidized access to treatments for juvenile arthritis, rare liver diseases, and multiple sclerosis. This expansion offers significant relief to patients and their families who would otherwise face crippling costs. The initiative aims to make essential medications more accessible and affordable, easing the financial strain associated with managing chronic illnesses.
One of the key additions is the expanded listing of Adalimumab (Humira®) to include the treatment of juvenile idiopathic arthritis. Humira was already available on the PBS for other paediatric immune-mediated inflammatory diseases (IMIDs) like Crohn’s disease, ulcerative colitis, and chronic plaque psoriasis, but this expansion brings much-needed relief for young arthritis sufferers. IMIDs are a group of conditions characterized by painful inflammation in the joints, gut, or skin. These conditions can severely impact a child's development, leading to long-term disabilities and disrupting their education and daily routines. Think about missing out on school trips, sports, or even just playing with friends because of constant pain. Humira works by modulating the immune system, reducing inflammation, and helping children regain mobility, participate in everyday activities, and enjoy a better quality of life. It essentially allows them to be kids again. An estimated 18,500 to 30,100 Australians aged 0 to 24 are estimated to be living with arthritis.
Health Minister Mark Butler emphasized the significant financial burden these medications can place on families. Without the PBS subsidy, a single script of Humira could cost patients and their families around $650. “The medicines we’re listing are life changing for people with distressing and even deadly conditions,” the Minister said. “Without the PBS, Australian patients would pay thousands of dollars instead of the newly reduced maximum of $25 per script, or just $7.70 for those who hold a concession card. The PBS is one of the most trusted government services in Australia and we’re committed to strengthening it by adding the latest treatments recommended by our experts.” The Minister's words underscore the critical role the PBS plays in ensuring equitable access to healthcare for all Australians.
But Humira isn't the only medication getting a boost. Two other significant additions to the PBS are Odevixibat (Bylvay®) and Ublituximab (Briumvi®).
Odevixibat (Bylvay®) has been listed for the first time on the PBS for the treatment of progressive familial intrahepatic cholestasis (PFIC). PFIC is a group of rare genetic liver diseases, primarily affecting children, that can also occur in adults. It causes a build-up of bile acids in the liver, leading to severe itching, poor sleep, and progressive liver damage. In severe cases, it can even necessitate a liver transplant. Bylvay works by reducing bile acid levels in the gut, alleviating itching and improving the overall well-being of patients and their families. PFIC is incredibly rare, affecting an estimated one in 50,000 to one in 100,000 live births globally. The financial implications for families without the PBS subsidy are staggering, with a single script potentially costing over $200,000. And this is the part most people miss... access to such specialized medications can be a matter of life and death, particularly for children with rare conditions like PFIC.
Ublituximab (Briumvi®) joins the PBS list for the first time as a treatment for relapsing-remitting multiple sclerosis (RRMS). RRMS is an autoimmune disease that damages the central nervous system, often leading to debilitating symptoms and long-term disability. It can profoundly impact a person's mobility, vision, and independence, significantly affecting their quality of life. Briumvi targets the B-cells that drive inflammation in multiple sclerosis, helping to reduce relapses, slow disease progression, and improve overall quality of life. In 2024, more than 14,000 patients accessed a comparable treatment through the PBS. Without subsidy, patients might pay $15,000 per script.
The PBS is a cornerstone of Australia's healthcare system, operating under the broader National Medicines Policy, which aims to meet medication and related service needs to achieve both optimal health outcomes and economic objectives. Under the scheme, the government subsidizes the cost of medicine for a wide range of medical conditions, with most of the listed medicines dispensed by pharmacists and used by patients at home.
The PBS began as a limited scheme in 1948, initially providing free medicines for pensioners and a list of 139 “life-saving and disease preventing” medicines free of charge for others in the community. From humble beginnings, it has grown to encompass more than 900 medicines, covering over 5000 different brands. The PBS Schedule, which lists all the medicines available to be dispensed to patients at a government-subsidized price, is managed by the Department of Health, Disability and Ageing and administered by Services Australia.
This expansion of the PBS is undoubtedly a positive step, offering hope and financial relief to thousands of Australians. But, is it enough? Are there other barriers to access that need to be addressed, such as geographical limitations or awareness gaps? How can we ensure that the PBS continues to evolve to meet the ever-changing healthcare needs of the Australian population? What are your thoughts on the PBS and its role in providing affordable healthcare? Share your opinions and experiences in the comments below!
